Staffordshire mother and son welcome cutting edge cancer research
A woman whose identical twin boys both endured cancer treatment, before one died at the age of 12, has welcomed cutting edge radiotherapy research. Julie Parton's son Ben died from a brain tumour, but just two weeks after Ben's funeral, his brother Jack was diagnosed with leukaemia. Julie and Jack, who is now cancer free, have been to see radiotherapy researchers at the University of Birmingham - one of only seven centres with equipment in the UK - which could improve outcomes for those with hard to treat tumours.The mum and son said seeing the work going on - boosted by a £1m investment from Cancer Research UK and £5,000 they have raised - has given them hope.
Born a minute apart, Jack and Ben were inseparable. Ben, who was an extrovert, was adored by his brother."He was the more outgoing, the more adventurous and you used to follow him, didn't you," Julie said, smiling at Jack at their home near near Cannock.Jack recalled: "He was good fun, we'd play football in the street, go to the park together, do everything together."
In 2019, when he was just 11, Ben was diagnosed with a glioblastoma - a rare brain tumour. Despite surgery and radiotherapy he died eight months later. Just a fortnight after Ben's funeral, Jack was diagnosed with leukaemia.
"It was horrendous, just losing one child and then being told your only existing child's got another form of cancer, it was really upsetting. And I just said, [to the doctors], 'You can't let him die'.""And they didn't," said Julie.
Jack endured more than three years of chemotherapy and immunotherapy.Now 17 and cancer free, he is an apprentice carpenter and is learning to drive. Cancer Research UK has made the University of Birmingham part of a multimillion-pound UK-wide radiation research network called RadNet. Jack and his mum have visited scientists to find out more. The university also has the UK's only neutron accelerator, allowing scientists to study groundbreaking developments in an alternative to radiotherapy that uses boron neutron capture therapy.Scientists hope the therapy could in future give fresh hope to patients with aggressive tumours, like Ben had.
Prof Jason Parsons, chair of radiation biology at the university, explained: "This is a more effective cancer treatment for patients, particularly for brain tumours, for head and neck tumours, so it's a lot more effective than conventional radiotherapy, so it damages tumour cells in more detail."We're hoping through the research we are performing that in the next probably five to 10 years we'll be able to develop the research, which will then enable for this to be clinically approved and used in the UK."
What Julie and Jack have seen has given them insight into how tumours like Ben's could be better treated in future."I want more therapies available because there weren't many options when he was alive, it was only a certain amount of things that could be done," Ben said."I know it's a long way off but it's a start, and it's a future," Julie added.
Julie donated Ben's tumour to scientists when it was removed."If it could help even just one child, I would be happy to donate anything," she said.Jack and Julie have raised more than £5,000 to various organisations for research, something they are passionate about.
Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
To Exist as I am by Grace Spence Green: Don't ignore me - and don't pity me, either
To Exist as I am: A Doctor's Notes on Recovery and Radical Acceptance by Grace Spence Green (Wellcome £16.99, 244pp) On October 17, 2018 Grace Spence Green, 22, a fourth-year medical student, was walking through the atrium of Westfield Shopping Centre in east London towards the tube station when a stranger jumped head first from the top-floor balcony and landed on her neck. The fact that she happened to be walking past at that moment meant Grace broke the man's fall and thus saved his life. But his fall broke her spinal cord. She was paralysed for life, from the chest down. The two would never exchange words. She doesn't even mention the man's name in this powerful and excoriating memoir. On the night of the accident, he happened to be in the bay beside hers in A&E, just for one night. Much later, she discovered he was a migrant who'd been high on weed. He was sentenced to four years in jail for grievous bodily harm, released after serving two, and then deported. She doesn't feel bitterness towards 'The Man', as she calls him, or even any emotional connection. All of her anger, and there's a great deal of it, is directed towards us, the general public, for getting things so wrong in what we say to disabled people, and how we treat them. Prepare to be severely chastened – and re-educated. Grace says she doesn't desire our insatiable curiosity, or our pity, yet she invokes both, strongly, in her visceral account of the aftermath of that fateful day. The week in a high-dependency unit 'in a warm, fuzzy, opioid dream'; the 26 metal staples put down the middle of her back by the surgeon Dr Bull; the eeriness of the 'bloodless injury', which nonetheless wrecked her body; the ominous words spoken by the doctors three months later, at the official prognosis and diagnosis meeting: 'It would be good to see things changing over the next few weeks.' But things did not change. Sensation did not come back to her legs or toes. Up to then, part of her still believed that the operation would 'fix' her, and make everything go back to how it was before. Now, 'my seemingly impenetrable bubble of denial had burst'. It would take eight months for the fact that the injury was permanent, and that she would never walk again, to sink fully into her brain. At the Royal National Orthopaedic Rehabilitation Centre in Stanmore, north-west London, Grace was relieved as well as shocked to meet other young people in a similar plight. There was competitiveness among some of the patients. 'Are you walking yet?' she was asked. 'Not yet,' she'd reply. She recalls the bleakness of returning to the Centre after a few days at home over Christmas with her loving family and her steadfast boyfriend Nathan, to whom she would later become engaged. She thought back to the weekend before the accident: she and her friends had sat up all night round a bonfire in a Kentish field, chatting and laughing. 'Now I find I have lost control of every bodily function, in a place I cannot leave.' She was told she'd need to insert a single-use catheter into herself every four hours for the rest of her life. She felt 'waves of hatred' towards the wheelchair at first – until she learned to appreciate it as a tool, just as spectacles are a tool. She now can't stand the expression 'wheelchair-bound'. She bristles when people use the word 'inspirational' to describe her progress – she calls it 'inspiration porn', as if people get some kick from her 'tragic' story. 'I've heard the word so many times that it's lost all meaning.' But it's hard not to see her as an inspiration. She completed her medical studies, became a junior doctor in 2021 and now makes it her business to protect the dignity and autonomy of her patients, in a way that sometimes did not happen to her. She notices that as soon as she takes off her lanyard and stethoscope at the end of the working day, she becomes 'hyper-visible and utterly ignored'. That's the daily status of too many disabled people. She does not like her wheelchair to be pushed or pulled 'in the name of helping'. It undermines her autonomy. She also hates it when people hold the door open for her: 'It can be much easier for me to do it myself, rather than having to duck under an outstretched arm.' We should say to a disabled person, 'You let me know if you need help.' Questions and remarks that annoyed her while she was in hospital were: 'Is there anything that can be done?'; 'Are you getting better?'; and 'It's not permanent, I hope?' So, don't say those. But also, whatever you do, don't say to a disabled person that you don't see them as disabled. ' 'You're not looking at me properly,' I want to say. 'You are missing a huge part of me by trying to ignore this." ' And on no account must you say you pity her. 'When people do that, it feels as if they have forced their way into my world and spat on it.' Nor must you single a disabled person out for notice, even out of kindness. Once, back at medical school, an instructor was on the phone cross that a lesson was starting late. 'And we have a lady in a WHEELCHAIR waiting in the corridor, so it's just unacceptable.' Grace felt 'shaken, to be singled out in a crowd of peers.' Later, the instructor said, 'Sorry – I'm really sorry, I didn't mean to be offensive, I'm sorry, it was just a stressful situation.' Grace didn't 'interrupt her ramble'. She just looked directly into her eye and said, 'OK'. 'Micro-aggression upon microaggression, piling up,' Grace calls all this. For her, it's an uphill battle to defend her happiness, when the assumption is that she's the 'poor brave tragic girl', whose boyfriend was 'a hero' not to desert her. Every October 17, she celebrates her 'alive day'. The fact that her wheelchair is full of scratches and dents is a sign of a life lived to the full. 'I am going to enjoy a life that society has told me is not worthy. That is activism.'
The Independent
3 hours ago
- The Independent
NHS green lights ‘Trojan horse' treatment that attacks cancer cells from inside
Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, health officials have announced. The targeted therapy, belantamab mafodotin, also known as Blenrep, has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, according to studies. Approximately 1,500 patients annually with multiple myeloma, an incurable bone marrow cancer, are expected to benefit from this new treatment. The National Institute for Health and Care Excellence (Nice) has approved Blenrep, manufactured by GlaxoSmithKline, for use within the NHS. NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be available to patients whose cancer has advanced or has not responded to initial treatments. Administered as an infusion every three weeks alongside other cancer drugs, this antibody drug targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
-on-wheat-in-natural-habitat.jpeg%3Ftrim%3D437%2C338%2C168%2C320%26width%3D1200%26height%3D800%26crop%3D1200%3A800&w=3840&q=100)
The Independent
3 hours ago
- The Independent
‘Musical insect' extinct in the UK for over 30 years to be brought back from France
A species of musical insect extinct in the UK has been reintroduced to the country from France, conservationists have said. The Species Recovery Trust released 11 New Forest cicadas this week into a habitat at Paultons Park, near the Hampshire woods where they previously lived. The New Forest cicada, or Cicadetta montana, used to be found across the New Forest, but the last confirmed sightings were in the 1990s. Conservationists believe changes to land management led to their extinction in the UK. Charlotte Carne, Species Recovery Trust project officer, said: "This has been a really challenging project so it's amazing to see New Forest cicadas in England after all this time." 'It's like bringing them back from the dead.' The adult insects are black with distinct golden rings and transparent wings, with females growing to about 5cm while males are slightly smaller. The Trust recruited a French entomologist this week who captured the 11 female cicadas in northern France and had them shipped to the UK on Wednesday. It is understood that some of the insects are already pregnant and have been laying eggs in their specially created habitat, which is full of their favourite plants such as raspberry canes and hazel tree saplings. Because cicadas spend at least four years underground as nymphs, the trust will not know until 2029 at the earliest whether this phase of the project has been successful. If they survive, the conservationists can release the adults at secret locations in the New Forest. In the meantime, the team said it hopes to import more cicadas from France to continue the breeding programme at Paultons Park. They are also studying populations of the same species in Slovenia to learn more about their behaviour. Dominic Price, Species Recovery Trust director, said: 'We believe the New Forest cicada probably went extinct because of changes to the way land was managed, but we have worked with Forestry England to put the right kind of management in place. 'What's more, we think that our warming climate could also favour their survival, so we are very hopeful that one day soon, cicadas will sing in the New Forest again.' The first-of-its-kind project has been funded by Natural England, the Swire Charitable Trust and the Valentine Charitable Trust. Graham Horton, acting deputy director for the Thames Solent Area Team at Natural England, said: 'This project represents a remarkable achievement, showcasing the dedication, innovation and teamwork that made it possible. 'After years of absence, we finally have New Forest cicada on English shores again and we look forward to the next phase of the project to explore re-establishing this species in the New Forest.'
